Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 06 2020
30 06 2020
Historique:
received:
02
03
2020
accepted:
08
06
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Pancreatic neuroendocrine neoplasms (PanNENs) are rare tumours that compose 1-2% of all pancreatic tumours. Patients with metastatic grade 3 neoplasia are usually treated with chemotherapy but have a poor progression-free and overall survival. According to the WHO 2017 classification, they are divided into neuroendocrine tumours (NETs) G3 and neuroendocrine carcinomas (NECs). Despite the new classification, new diagnostic and prognostic biomarkers are needed to sub-categorise the patients and to help guide therapy decisions. Blood from 42 patients and 42 healthy controls were screened for the presence of 92 proteins with the Immuno-Oncology panel using the Proximity Extension Assay provided by Olink Biosciences. Immunohistochemical staining of FAS ligand (FASLG) was performed on 16 patient tumour specimens using a commercial antibody. Fifty-four out of 87 evaluable proteins differed significantly in concentration between blood from patients and blood from healthy controls. FASLG was the only protein for which the concentration in blood was significantly lower in patients compared to controls and the levels correlated negatively to Ki-67 index. Seven of 14 evaluable PanNEN G3 specimens showed FASLG immunoreactivity in the tumour cells while there was scattered immunoreactivity in immune cells. Positive FASLG immunoreactivity correlated to well-differentiated morphology. FASLG concentration in blood was significantly lower in patients with pancreatic NENs G3 compared to controls, and the expression in tumour tissue was variable. Furthermore, FASLG was negatively correlated to Ki-67 and was more frequently expressed in well-differentiated tumours. Taken together, these results may suggest a role of FASLG in PanNENs.
Identifiants
pubmed: 32606315
doi: 10.1038/s41598-020-67670-7
pii: 10.1038/s41598-020-67670-7
pmc: PMC7327066
doi:
Substances chimiques
Fas Ligand Protein
0
Ki-67 Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10639Références
Fraenkel, M., Kim, M. K., Faggiano, A. & Valk, G. D. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract. Res. Clin. Gastroenterol. 26, 691–703. https://doi.org/10.1016/j.bpg.2013.01.006 (2012).
doi: 10.1016/j.bpg.2013.01.006
pubmed: 23582913
Halfdanarson, T. R., Rubin, J., Farnell, M. B., Grant, C. S. & Petersen, G. M. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr. Relat. Cancer 15, 409–427. https://doi.org/10.1677/ERC-07-0221 (2008).
doi: 10.1677/ERC-07-0221
pubmed: 18508996
pmcid: 2693313
Yao, J. C. et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26, 3063–3072. https://doi.org/10.1200/JCO.2007.15.4377 (2008).
doi: 10.1200/JCO.2007.15.4377
pubmed: 18565894
pmcid: 18565894
Oberg, K. E. Gastrointestinal neuroendocrine tumors. Ann. Oncol. 21(Suppl 7), 72–80. https://doi.org/10.1093/annonc/mdq290 (2010).
doi: 10.1093/annonc/mdq290
Tang, L. H., Basturk, O., Sue, J. J. & Klimstra, D. S. A practical approach to the classification of WHO Grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am. J. Surg. Pathol. 40, 1192–1202. https://doi.org/10.1097/PAS.0000000000000662 (2016).
doi: 10.1097/PAS.0000000000000662
pubmed: 27259015
pmcid: 4988129
Milione, M. et al. The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology 104, 85–93. https://doi.org/10.1159/000445165 (2017).
doi: 10.1159/000445165
pubmed: 26943788
Coriat, R., Walter, T., Terris, B., Couvelard, A. & Ruszniewski, P. Gastroenteropancreatic well-differentiated grade 3 neuroendocrine tumors: review and position statement. Oncologist 21, 1191–1199. https://doi.org/10.1634/theoncologist.2015-0476 (2016).
doi: 10.1634/theoncologist.2015-0476
pubmed: 5061528
pmcid: 5061528
Sorbye, H., Baudin, E. & Perren, A. The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond. Endocrinol. Metab. Clin. N. Am. 47, 683–698. https://doi.org/10.1016/j.ecl.2018.05.001 (2018).
doi: 10.1016/j.ecl.2018.05.001
Kloppel, G. et al. Pancreatic neuroendocrine tumors: update on the new World Health Organization Classification. AJSP Rev. Rep. 22, 233–239. https://doi.org/10.1097/Pcr.0000000000000211 (2017).
doi: 10.1097/Pcr.0000000000000211
Strosberg, J. R. et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 39, 799–800. https://doi.org/10.1097/MPA.0b013e3181ebb56f (2010).
doi: 10.1097/MPA.0b013e3181ebb56f
pubmed: 20664477
pmcid: 3100733
Janson, E. T. et al. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol. 53, 1284–1297. https://doi.org/10.3109/0284186X.2014.941999 (2014).
doi: 10.3109/0284186X.2014.941999
pubmed: 25140861
Garcia-Carbonero, R. et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology 103, 186–194. https://doi.org/10.1159/000443172 (2016).
doi: 10.1159/000443172
pubmed: 26731334
Vinik, A. I. & Raymond, E. Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib. Ther. Adv. Gastroenterol. 6, 396–411. https://doi.org/10.1177/1756283X13493878 (2013).
doi: 10.1177/1756283X13493878
Tang, L. H. et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin. Cancer. Res. 22, 1011–1017. https://doi.org/10.1158/1078-0432.CCR-15-0548 (2016).
doi: 10.1158/1078-0432.CCR-15-0548
pubmed: 26482044
Boons, G., Vandamme, T., Peeters, M., Van Camp, G. & Op de Beeck, K. Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: moving towards liquid biopsies. Rev. Endocr. Metab. Disord. 20, 333–351. https://doi.org/10.1007/s11154-019-09508-w (2019).
doi: 10.1007/s11154-019-09508-w
pubmed: 31368038
Assarsson, E. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE 9, e95192. https://doi.org/10.1371/journal.pone.0095192 (2014).
doi: 10.1371/journal.pone.0095192
pubmed: 24755770
pmcid: 3995906
Peter, M. E. et al. The role of CD95 and CD95 ligand in cancer. Cell Death Differ. 22, 549–559. https://doi.org/10.1038/cdd.2015.3 (2015).
doi: 10.1038/cdd.2015.3
pubmed: 25656654
pmcid: 4356349
Itoh, N. et al. The polypeptide encoded by the cDNA for human cell surface antigen FAS can mediate apoptosis. Cell 66, 233–243 (1991).
doi: 10.1016/0092-8674(91)90614-5
Suda, T. et al. Expression of the FAS ligand in cells of T cell lineage. J. Immunol. 154, 3806–3813 (1995).
pubmed: 7706720
Kagi, D. et al. FAS and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265, 528–530 (1994).
doi: 10.1126/science.7518614
Suda, T., Takahashi, T., Golstein, P. & Nagata, S. Molecular cloning and expression of the FAS ligand, a novel member of the tumor necrosis factor family. Cell 75, 1169–1178 (1993).
doi: 10.1016/0092-8674(93)90326-L
Ashkenazi, A. & Dixit, V. M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11, 255–260 (1999).
doi: 10.1016/S0955-0674(99)80034-9
Waring, P. & Mullbacher, A. Cell death induced by the FAS/FAS ligand pathway and its role in pathology. Immunol. Cell Biol. 77, 312–317. https://doi.org/10.1046/j.1440-1711.1999.00837.x (1999).
doi: 10.1046/j.1440-1711.1999.00837.x
pubmed: 10457197
Peter, M. E. et al. The role of CD95 and CD95 ligand in cancer. Cell Death Differ. 22, 885–886. https://doi.org/10.1038/cdd.2015.25 (2015).
doi: 10.1038/cdd.2015.25
pubmed: 25849030
pmcid: 4392084
Owonikoko, T. K. et al. Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer. Cancer 119, 1503–1511. https://doi.org/10.1002/cncr.27937 (2013).
doi: 10.1002/cncr.27937
pubmed: 23340930
pmcid: 3799834
Hamilton, N. A. et al. Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. Surgery 152, 107–113. https://doi.org/10.1016/j.surg.2012.02.011 (2012).
doi: 10.1016/j.surg.2012.02.011
pubmed: 22503317
pmcid: 3377849
Liu, W. H. & Wang, D. G. Apoptosis regulating genes in neuroendocrine tumors. Histol. Histopathol. 15, 851–859. https://doi.org/10.14670/HH-15.851 (2000).
doi: 10.14670/HH-15.851
pubmed: 10963129
Bernstorff, W. V. et al. FAS (CD95/APO-1) and FAS ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. Cancer 94, 2552–2560. https://doi.org/10.1002/cncr.10549 (2002).
doi: 10.1002/cncr.10549
pubmed: 12173320
Kornmann, M., Ishiwata, T., Kleeff, J., Beger, H. G. & Korc, M. FAS and Fas-ligand expression in human pancreatic cancer. Ann. Surg. 231, 368–379. https://doi.org/10.1097/00000658-200003000-00010 (2000).
doi: 10.1097/00000658-200003000-00010
pubmed: 10714630
pmcid: 1421008
Kornmann, M., Ishiwata, T., Maruyama, H., Beger, H. G. & Korc, M. Coexpression of FAS and FAS-ligand in chronic pancreatitis: correlation with apoptosis. Pancreas 20, 123–128. https://doi.org/10.1097/00006676-200003000-00003 (2000).
doi: 10.1097/00006676-200003000-00003
pubmed: 10707926
Trivedi, P. M. et al. Soluble FAS ligand is not required for pancreatic islet inflammation or beta-cell destruction in non-obese diabetic mice. Cell Death Discov. 5, 136 (2019).
doi: 10.1038/s41420-019-0217-z
Lu, C. & Liu, K. Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy. Transl. Cancer Res. 6, S652–S654 (2017).
doi: 10.21037/tcr.2017.05.32
Afshar-Sterle, S. et al. FAS ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. Nat. Med. 20, 283–290. https://doi.org/10.1038/nm.3442 (2014).
doi: 10.1038/nm.3442
pubmed: 24487434
Ryan, A. E., Shanahan, F., O’Connell, J. & Houston, A. M. Addressing the “FAS counterattack” controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res. 65, 9817–9823. https://doi.org/10.1158/0008-5472.CAN-05-1462 (2005).
doi: 10.1158/0008-5472.CAN-05-1462
pubmed: 16267003
Krammer, P. H. CD95’s deadly mission in the immune system. Nature 407, 789–795. https://doi.org/10.1038/35037728 (2000).
doi: 10.1038/35037728
pubmed: 11048730
Bennett, M. W. et al. The FAS counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with FAS ligand expression by human esophageal carcinoma. J. Immunol. 160, 5669–5675 (1998).
pubmed: 9605174
Okada, K. et al. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin. Cancer. Res. 6, 3560–3564 (2000).
pubmed: 10999744
Munakata, S. et al. Expressions of FAS ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br. J. Cancer 82, 1446–1452 (2000).
doi: 10.1054/bjoc.1999.1073
Houston, A. et al. FAS ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo. Int. J. Cancer 107, 209–214. https://doi.org/10.1002/ijc.11392 (2003).
doi: 10.1002/ijc.11392
pubmed: 12949796
Pryczynicz, A., Guzinska-Ustymowicz, K. & Kemona, A. FAS/FasL expression in colorectal cancer. An immunohistochemical study. Folia Histochem. Cytobiol. 48, 425–429. https://doi.org/10.2478/v10042-010-0058-3 (2010).
doi: 10.2478/v10042-010-0058-3
pubmed: 21071349
Singhi, A. D. & Klimstra, D. S. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases. Histopathology 72, 168–177. https://doi.org/10.1111/his.13408 (2018).
doi: 10.1111/his.13408
pubmed: 29239037
Haupt, S., Berger, M., Goldberg, Z. & Haupt, Y. Apoptosis—the p53 network. J. Cell. Sci. 116, 4077–4085. https://doi.org/10.1242/jcs.00739 (2003).
doi: 10.1242/jcs.00739
pubmed: 12972501
Aubrey, B. J., Kelly, G. L., Janic, A., Herold, M. J. & Strasser, A. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?. Cell Death Differ. 25, 104–113. https://doi.org/10.1038/cdd.2017.169 (2018).
doi: 10.1038/cdd.2017.169
pubmed: 29149101
Metheny-Barlow, L. J. & Li, L. Y. The enigmatic role of angiopoietin-1 in tumor angiogenesis. Cell Res. 13, 309–317. https://doi.org/10.1038/sj.cr.7290176 (2003).
doi: 10.1038/sj.cr.7290176
pubmed: 14672554
Mandelboim, O. et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409, 1055–1060. https://doi.org/10.1038/35059110 (2001).
doi: 10.1038/35059110
pubmed: 11234016
Kawamura, M. et al. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. Eur. J. Cancer 48, 2244–2251. https://doi.org/10.1016/j.ejca.2011.11.032 (2012).
doi: 10.1016/j.ejca.2011.11.032
pubmed: 22197219
Chicheportiche, Y. et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 272, 32401–32410. https://doi.org/10.1074/jbc.272.51.32401 (1997).
doi: 10.1074/jbc.272.51.32401
pubmed: 9405449
Wiley, S. R. et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15, 837–846. https://doi.org/10.1016/s1074-7613(01)00232-1 (2001).
doi: 10.1016/s1074-7613(01)00232-1
pubmed: 11728344
Kampf, C., Olsson, I., Ryberg, U., Sjostedt, E. & Ponten, F. Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas. J. Vis. Exp. https://doi.org/10.3791/3620 (2012).
doi: 10.3791/3620
pubmed: 22688270
pmcid: 3468196
Uhlen, M. et al. Proteomics tissue-based map of the human proteome. Science 347, 1260419. https://doi.org/10.1126/science.1260419 (2015).
doi: 10.1126/science.1260419
pubmed: 25613900
pmcid: 25613900
Chen, S. Y., Feng, Z. & Yi, X. A general introduction to adjustment for multiple comparisons. J. Thorac. Dis. 9, 1725–1729. https://doi.org/10.21037/jtd.2017.05.34 (2017).
doi: 10.21037/jtd.2017.05.34
pubmed: 28740688
pmcid: 5506159